New drug cocktail aims to boost breast cancer treatment
NCT ID NCT06637306
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This early-phase trial tests whether adding dupilumab (an allergy drug) to standard chemotherapy and immunotherapy is safe for people with locally advanced triple-negative breast cancer. About 15 participants will receive the combination before surgery. The main goal is to check for severe side effects, and researchers will also see if the tumor shrinks or disappears.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mount Sinai Health System
RECRUITINGNew York, New York, 10029, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.